-
US Peptide Regulations May Soon Come Into Sharper Focus
Ongoing regulatory reviews are expected to clarify how peptides are classified, marketed, and sold in the United States. The outcome could reshape access to compounded and research-use peptides alike.
-
Peptide and Nanobody Drug Conjugates Gain Momentum as Targeted Therapy Platforms
A growing number of drug developers are building conjugate therapies around peptides and nanobodies instead of full-sized antibodies, aiming to combine precise targeting with smaller, more versatile drug scaffolds. The trend reflects broader efforts to refine how targeted payloads are delivered to specific tissues and cell types.
-
FDA Advisory Panel Recommends BPC-157 for Compounding Pharmacy List
An FDA advisory committee has voted to recommend BPC-157, a peptide widely discussed in research and wellness circles, for inclusion on the agency’s list of substances eligible for pharmacy compounding. The vote is a procedural step, not a final approval or endorsement of safety and efficacy.